Maged Shenouda - 12 Dec 2025 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role
Chief Financial Officer
Signature
/s/ Maged Shenouda
Issuer symbol
RLMD
Transactions as of
12 Dec 2025
Net transactions value
+$48,060
Form type
4
Filing time
16 Dec 2025, 09:30:24 UTC
Previous filing
06 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Shenouda Maged Chief Financial Officer C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES /s/ Maged Shenouda 16 Dec 2025 0001658369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLMD Common Stock Purchase $48,060 +11,665 +1.5% $4.12 800,000 15 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLMD Stock Appreciation Rights Award $0 +828,000 $0.000000 828,000 12 Dec 2025 Common Stock 828,000 $4.06 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock appreciation rights vest in 16 equal quarterly installments commencing on March 12, 2026.